Type 2 Diabetes News and Research

Latest Type 2 Diabetes News and Research

Liver tumors associated with metabolic syndrome differ from other tumors

Liver cancer in patients whose only risk factor is metabolic syndrome has distinct forms and structures compared to other liver tumors.

25 Feb 2009

Compounds that trigger beta cell replication identified

Researchers at the Genomics Institute of the Novartis Research Foundation (GNF) have identified a set of compounds that can trigger the proliferation of insulin-producing cells in the pancreas, using sophisticated high-throughput screening techniques.

25 Feb 2009

Could our mother's diet at time we are conceived set the course for our future health?

This intriguing question is at the heart of a new study based on an "experiment of nature" being conducted by Wellcome Trust-funded researchers.

25 Feb 2009

Plasminogen activator inhibitor type-1 -- a potential link between heart failure and diabetes

Researchers at the University of Vermont Cardiovascular Research Institute, Colchester, Vermont have found that increased expression in the heart of plasminogen activator inhibitor type-1 (PAI-1) is profibrotic.

24 Feb 2009

Mindset BioPharmaceuticals receives notice of allowance for European patent related to insulin sensitizers in dementia and memory loss

Mindset BioPharmaceuticals (USA) Inc ("MINDSET") a company privately held by MPM Capital and other shareholders announced today that it has received a Notice of Allowance in Europe related to patent applications describing the use of insulin sensitizer drugs for the prevention and treatment of memory loss.

24 Feb 2009

Scientists mine drugs database for new diabetes treatment

Scientists funded by the Biotechnology and Biological Sciences Research Council have harnessed a new drug discovery tool to identify a new player in the body's insulin secretion process.

22 Feb 2009

Investing in personalized medicine will benefit Canada

Canada has the opportunity to be an international leader in personalized medicine and needs to invest in this area for the health of Canadians and to reap the benefits of job creation, writes Dr. Thomas Hudson in a commentary http://www.cmaj.ca/cgi/rapidpdf/cmaj.1090199 released online today in CMAJ ( Canadian Medical Association Journal ).

20 Feb 2009

GlaxoSmithKline starts phase III trial of Syncria (albiglutide) type 2 diabetes medication

GlaxoSmithKline has announced initiation and dosing of the first patient of the Phase III clinical trial programme to evaluate the efficacy, safety and tolerability of the investigational GLP-1 (Glucagon-like peptide 1) agonist Syncria (albiglutide) in men and women with type 2 diabetes.

18 Feb 2009